Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company's ambition to address the Long COVID crisis as its leadership met with Congress on Capitol Hill last week.

"It was an honor to meet with congressional teams in Washington, D.C., to address the urgent challenge of Long COVID and present Tevogen Bio's proprietary ExacTcell technology as a promising solution to this escalating crisis, which is impacting both individual patients and the broader economy...